Nuzenio

Tipranks Analyst Reaffirms

Tipranks Analyst Reaffirms news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 2 publisher sources 100/100 entity strength

Latest news

Analyst Piyush Avasthy Reaffirms Buy on Ralliant Corporation, Lifts Price Target to $82 on Structural Growth and Margin Expansion - TipRanksTipRanks · Mon, 10 Aug 2026 09:55:23 GMTMicrochip Recovery Accelerates as Analyst Reaffirms Buy Rating and Maintains $120 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 16:04:15 GMTAnalyst Maintains Buy on Nuvation Bio, Reaffirming $21 Price Target Amid Long-Term IBTROZI Growth Prospects - TipRanksTipRanks · Fri, 07 Aug 2026 13:29:07 GMTDraftKings Kept at Buy as Analyst Sees Transient EBITDA Headwinds, Reaffirms Long-Term Outlook and Maintains $35 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 12:30:43 GMTAnalyst Reaffirms Buy on Korro Bio, Citing Undervalued OPERA RNA Editing Platform and Multi-Billion-Dollar Pipeline Potential - TipRanksTipRanks · Fri, 07 Aug 2026 12:27:18 GMTAnalyst Reaffirms Buy Rating on Via, Maintains $55 Price Target Amid Strong Pipeline and Growth Visibility - TipRanksTipRanks · Fri, 07 Aug 2026 07:21:09 GMTAnalyst Reaffirms Buy on Latham Amid Market Outperformance and Path to Margin Recovery - TipRanksTipRanks · Fri, 07 Aug 2026 02:35:42 GMTAnalyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver - TipRanksTipRanks · Thu, 06 Aug 2026 17:52:17 GMT

Timeline

Mon, 10 Aug 2026 09:55:23 GMTAnalyst Piyush Avasthy Reaffirms Buy on Ralliant Corporation, Lifts Price Target to $82 on Structural Growth and Margin Expansion - TipRanks
Fri, 07 Aug 2026 16:04:15 GMTMicrochip Recovery Accelerates as Analyst Reaffirms Buy Rating and Maintains $120 Price Target - TipRanks
Fri, 07 Aug 2026 13:29:07 GMTAnalyst Maintains Buy on Nuvation Bio, Reaffirming $21 Price Target Amid Long-Term IBTROZI Growth Prospects - TipRanks
Fri, 07 Aug 2026 12:30:43 GMTDraftKings Kept at Buy as Analyst Sees Transient EBITDA Headwinds, Reaffirms Long-Term Outlook and Maintains $35 Price Target - TipRanks
Fri, 07 Aug 2026 12:27:18 GMTAnalyst Reaffirms Buy on Korro Bio, Citing Undervalued OPERA RNA Editing Platform and Multi-Billion-Dollar Pipeline Potential - TipRanks
Fri, 07 Aug 2026 07:21:09 GMTAnalyst Reaffirms Buy Rating on Via, Maintains $55 Price Target Amid Strong Pipeline and Growth Visibility - TipRanks

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tipranks Analyst Reaffirms.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.